Encoberminogene rezmadenovec clinical trials
Also written XC001.
How each study uses encoberminogene rezmadenovec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the encoberminogene rezmadenovec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- XC001
- 3
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
XyloCor Therapeutics, Inc. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test encoberminogene rezmadenovec.
- Dec 2026Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABGPhase 2 · XyloCor Therapeutics, Inc.
- Jun 2027Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.Phase 2 · XyloCor Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses encoberminogene rezmadenovec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.RecruitingPhase 2XyloCor Therapeutics, Inc.NCT07048808Written as XC001
- Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABGNot yet recruitingPhase 2XyloCor Therapeutics, Inc.NCT07118449Written as XC001
- Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)CompletedPhase 1/2XyloCor Therapeutics, Inc.NCT04125732Written as AdVEGFXC1
Codes
What other systems call encoberminogene rezmadenovec · ClinicalTrials.gg INT015780
- UNII (FDA) 93TLW455ZZENCOBERMINOGENE REZMADENOVECOne source FDA
- NCI Thesaurus C179083Encoberminogene RezmadenovecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 93TLW455ZZ | ENCOBERMINOGENE REZMADENOVEC | One source FDA |
| NCI Thesaurus | C179083 | Encoberminogene Rezmadenovec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.